Physician profile
Stormiee D Eldred
NPI 1750687422
$1,273.92
in general payments reported to CMS, 2019-2025
25 companies · $326 in 2025
The $326 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $74.68 · 2022: $159 · 2023: $381 · 2024: $334 · 2025: $326.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,040.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,040.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $232.59 | 2022-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Otsuka America Pharmaceutical, INC. | $125.00 | 2025 | Rexulti |
| Inspire Medical Systems, INC. | $124.17 | 2024-2025 | Inspire |
| Astellas Pharma US INC | $118.55 | 2023-2025 | Veozah, Myrbetriq |
| Novo Nordisk INC | $81.75 | 2022-2025 | Wegovy, Rybelsus, Ozempic |
| Acadia Pharmaceuticals INC | $65.84 | 2021-2023 | Nuplazid |
| Janssen Pharmaceuticals, INC | $64.08 | 2022-2025 | Xarelto, Spravato |
| Exact Sciences Corporation | $41.90 | 2023-2024 | Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals LP | $41.77 | 2022-2023 | Farxiga, Breztri |
| Boston Scientific Corporation | $41.27 | 2024 | Wavewriter Alpha Prime 16 |
| Lilly USA, LLC | $37.40 | 2022 | |
| Xeris Pharmaceuticals, INC. | $35.30 | 2022-2023 | Gvoke Hypopen |
| Sumitomo Pharma America, INC. | $34.38 | 2024-2025 | Gemtesa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.65 | 2021-2024 | Ofev |
| Sun Pharmaceutical Industries INC. | $27.66 | 2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $25.61 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $22.97 | 2025 | |
| Phathom Pharmaceuticals, INC. | $21.69 | 2024 | Voquezna |
| Abbott Laboratories | $19.58 | 2023 | Proclaim |
| Idorsia Pharmaceuticals US INC | $18.10 | 2023 | Quviviq |
| Amgen INC. | $16.20 | 2023 | Repatha, Otezla |
| Lundbeck LLC | $15.64 | 2023 | Rexulti |
| Sanofi-Aventis U.S. LLC | $14.64 | 2025 | |
| Sunovion Pharmaceuticals INC. | $13.69 | 2022 | |
| Cequr Corporation | $3.49 | 2024 | Cequr Simplicity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stormiee Eldred listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.